Benefits of newer PCa drugs elucidated at AUA 2013

April 18, 2013

At this year's AUA annual meeting, data on some newer advanced prostate cancer drugs will shine the light on their clinical utility, according to J. Brantley Thrasher, MD, of the University of Kansas Medical Center, Kansas City.

This artice is part of the State of Urology 2013

In recent years, the AUA annual meeting has come on the heels of big-name drug approvals for advanced prostate cancer. That will not be the case this year, but data on some newer drugs will shine the light on their clinical utility, according to J. Brantley Thrasher, MD, of the University of Kansas Medical Center, Kansas City.

“Three abstracts speak to the benefits of newer agents for advanced prostate cancer over our standard LHRH analogs,” said Dr. Thrasher. “These large studies demonstrate the oncologic efficacy, pain-reducing effects, and cardiovascular safety of these newer agents.”

Including the abstracts cited above, here are Dr. Thrasher’s top picks for advanced prostate cancer from the 2013 AUA annual meeting:

 

713:Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy – Interim analysis of the COU-AA-302 phase 3 trial

Fred Saad

 

714: Pain and quality of life (QoL) analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases

Michael Tomblyn

 

719: Salvage Radiation Therapy After Recurrent Prostate Cancer: How Early Do We Need to Be?

Roberto Muller

 

724: Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer

Matthew Cooperberg

 

775: The Australian experience of the 'Man Plan' exercise program for patients with prostate cancer on androgen deprivation therapy

Lawrence Kim

 

777: Pooled Analysis of two protocols of intermittent hormonal therapy in advanced prostatic cancer

Fernando Calais da Silva, Jr.

 

781: Androgen deprivation therapy by a gonadotropin releasing hormone antagonist, degarelix, lowers the risk of cardiovascular events or death when compared to luteinising hormone-releasing agonists

Peter Albertsen

 

964: Cigarette smoking is associated with shorter time from radical prostatectomy to metastasis: Results from the SEARCH Database

Daniel Moreira

 

966: Oncologic outcomes following robotic-assisted laparoscopic vs. open radical prostatectomy for intermediate and high-risk prostate cancer

Chad Ritch

 

Dr. Thrasher also pointed out “excellent” plenary session presentations on four new clinical practice guidelines: castrate-resistant prostate cancer, detection of prostate cancer, follow-up care for renal cancer, and radiation following radical prostatectomy. Also recommended from the plenary session: a discussion on managing progressive prostate cancer.UT